PYC
PYC THERAPEUTICS LIMITED
$2.75
▼ -2.48%
Market cap
$2.70B
Turnover
$7,673,782
Last price
$2.75
Day change
-2.48%
Announcements
9
Range, past year
Open 1.030 · Low 0.847 · Now 2.750 · High 2.930
Open PYC in the full dashboard →
Charts, screener, momentum and signals across every ASX-listed code.
PYC momentum and trend analysis
Our analysis
Independent analysis generated by Stock Trade Intelligence
as at 2026-09-28.
Momentum quality
78/100
Wyckoff phase
Uptrend6d
Trend stage
Accelerating Trend
1 Day
-2.5%
1 Week
-1.4%
1 Month
+22.2%
1 Year
+177.8%
RSI
64
Avg daily range
5.1%
PYC THERAPEUTICS LIMITED scores 78 out of 100 for momentum quality, a reading rated high confidence. The score weighs trend structure, price consistency, volume backing and how long the move has held, so a high reading means a sustained trend rather than a single large day. Its trend is currently classified as Accelerating Trend.
On the Wyckoff cycle it sits in Uptrend, where it has been for 6 trading days. The weekly timeframe reads Uptrend, which agrees with the daily view.
Against the wider market it is currently outperforming and the institutional accumulation signal reads moderate.
What stands out
- Solid momentum quality (MQS 78)
- Trend R² 0.90 — highly linear uptrend
- Above SMA50 for 75 days
- Volume 1.7× 60-day avg
- RSI in healthy zone (64)
Points to watch
Nothing flagged for PYC on this reading.
Browse the whole market by signal:
ASX stocks in Wyckoff accumulationASX momentum stocks by trend qualityASX stocks breaking outASX stocks near 52-week highsPYC announcements
Recent price-sensitive releases.
- 2026-08-28 Appendix 4E Preliminary Final Report
- 2026-07-29 Quarterly Activities/Appendix 4C Cash Flow Report Commitments Test Entity - Fourth Quarter Activity Report | Commitments Test Entity - Fourth Quarter Cashflow Report
- 2026-07-22 PKD - Safety Committee Approves Dose Escalation
- 2026-07-21 ADOA Program Update
- 2026-05-07 PKD - Initiation of Multiple Dose Clinical Trial
- 2026-05-04 Presentation of Ophthalmology Clinical Trial Data at ARVO
- 2026-04-28 Quarterly Activities/Appendix 4C Cash Flow Report
More Health Care stocks
Most traded in the same sector.